Go-Less Men Receives Non-GMO Project Verification

IFF Health has attained Non-GMO Project Verification for its plant-based ingredient, Go-Less Men, which is formulated for healthy bladder function in men, and substantiated by a number of clincal trials.
 
The active ingredients in Go-Less Men are bioactive components found in pumpkin seeds, which have been used for similar purposes in the traditional medicine practices of Native Americans, and European herbal medicine dating back to the 14^th century.
 
Clinical studies have found that pumpkin seed extracts can help support improved urinary flow rate and voiding time, as well as reducing residual urine volume in men suffering form benign prostatic hyperplasia.
 
The Non-GMO Project has been one of the key certification bodies for driving growth within the dietary supplements industry due to increasing consumer awareness and preference for organically-produced foods and other consumer products. The Non-GMO Project is a non-profit organization that also provides consumer education and developmental strategies for sourcing additional non-GMO products.
 
“This certification reflects IFF’s commitment to develop the highest quality ingredients with full transparency and add value to our customer’s products,” Moran Werner Saido, product manager for IFF Health, said. “Go-Less Men is supported by science, non-allergenic, and has been shown to support the maintenance of a healthy bladder and prostate. It is also available in pharmaceutical grade.”
 
Go-Less Men is sourced from 100% European-grown pumpkin, and is manufactured using a proprietary decontamination procedure resulting in an oil-free pumpkin seed extract with increased stability, purity, and solubility. The process also eliminates susceptibility to rancidity.
 
A clinical trial that was recently published in the Journal of Medicinal Food found that 12 weeks of daily supplementation with 500 mg of Go-Less provided statistically significant reductions in symptoms based on the total International Prostate Symptom Score assessment, with 30% of men participating in the study reporting that their symptoms had reduced from either “moderate” or “severe” to “mild.”